Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9481729-B2
Application number	US-201414483330-A
Country	US
Kind code	B2
Filing date	Sep 11, 2014
Priority date	Sep 11, 2013
Publication date	Nov 1, 2016
Grant date	Nov 1, 2016

Abstract

Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.

First claim

I claim:

1. An isolated, bi-specific antibody or a bi-specific binding fragment thereof that specifically binds to human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor I receptor (IGF-IR),
wherein the isolated antibody or binding fragment thereof comprises the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, or antigen-binding fragments thereof, wherein at least two of the amino acid sequences comprise HER2 antigen binding regions and at least two of the amino acid sequences comprise IGF-IR antigen binding regions, and
wherein the antibody or binding fragment thereof has little detectable reactivity or physical association with other proteins or structures.

2. The isolated antibody or binding fragment thereof according to claim 1 , wherein CH3 of a constant region comprises SEQ ID NO: 5.

3. The isolated antibody or binding fragment thereof according to claim 1 , wherein CH3 of a constant region comprises SEQ ID NO: 6.

4. The isolated antibody or binding fragment thereof according to claim 1 , wherein CH3 of a constant region comprises SEQ ID NO: 7.

5. The isolated antibody or binding fragment thereof according to claim 1 , which specifically binds to human HER2 and human IGF-IR expressed on tumor or cancer cells.

6. The isolated antibody or binding fragment thereof according to claim 1 , which specifically binds to extracellular domains of human HER2 and human IGF-IR.

7. The isolated antibody or binding fragment thereof according to claim 1 , which comprises an F(ab′) 2 .

8. The isolated antibody or binding fragment thereof according to claim 1 , which is a humanized antibody.

9. A pharmaceutical composition comprising the isolated antibody or binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.

10. A method for treating a tumor or cancer, comprising administering to a subject in need of such treatment an effective amount of the isolated antibody or binding fragment thereof according to claim 1 .

11. The method according to claim 10 , wherein the subject is a human.

12. The method according to claim 10 , wherein the tumor or cancer is breast cancer, ovarian cancer, uterine cancer, prostate cancer, testicular germ cell tumor, glioblastoma multiforme, gastric cancer, esophagus cancer, lung cancer, liver cancer, and colon cancer.

13. A method of determining the presence of HER2 and/or IGF-IR in a mammal, comprising:
obtaining a test sample from a mammal;
contacting the test sample with the isolated antibody or binding fragment thereof according to claim 1 ; and
determining whether the bi-specific antibody has bound, wherein binding of the bi-specific antibody indicates the presence of HER2 and/or IGF-IR in the mammal.

Assignees

• Univ Hong Kong

Inventors

• Zhang Mei-Yun

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• G01N2333/475

  Assays involving growth factors · CPC title

• C07K2317/31

  multispecific · CPC title